FOSUN PHARMA Subsidiary Starts Phase II Trial of Novel DPP-1 Inhibitor FXS7553 for COPD

Bulletin Express08-13

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) announced that its wholly owned unit, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., has initiated a Phase II clinical trial in mainland China for FXS7553, an orally administered small-molecule DPP-1 inhibitor targeting chronic obstructive pulmonary disease (COPD).

FXS7553—formerly coded XH-S004—is being developed for multiple respiratory indications, including non-cystic fibrosis bronchiectasis, for which it is already in a separate Phase II study. To date, the group has invested approximately RMB 151.00 million in the compound’s research and development.

No DPP-1 inhibitor has yet secured marketing approval in China, underscoring the molecule’s potential first-in-class positioning domestically. The programme remains subject to the standard clinical and regulatory review process, and the company highlights inherent uncertainties in drug development, including possible safety or efficacy hurdles that could disrupt progress.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109029583?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 17:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109029583","market":"us","top_or_hot":-1,"title":"FOSUN PHARMA Subsidiary Starts Phase II Trial of Novel DPP-1 Inhibitor FXS7553 for COPD","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) announced that its wholly owned unit, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., has initiated a Phase II clinical trial in mainland China for FXS7553, an orally administered small-molecule DPP-1 inhibitor targeting chronic obstructive pulmonary disease (COPD).</p>\n<p>FXS7553—formerly coded XH-S004—is being developed for multiple respiratory indications, including non-cystic fibrosis bronchiectasis, for which it is already in a separate Phase II study. To date, the group has invested approximately RMB 151.00 million in the compound’s research and development.</p>\n<p>No DPP-1 inhibitor has yet secured marketing approval in China, underscoring the molecule’s potential first-in-class positioning domestically. The programme remains subject to the standard clinical and regulatory review process, and the company highlights inherent uncertainties in drug development, including possible safety or efficacy hurdles that could disrupt progress.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA Subsidiary Starts Phase II Trial of Novel DPP-1 Inhibitor FXS7553 for COPD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA Subsidiary Starts Phase II Trial of Novel DPP-1 Inhibitor FXS7553 for COPD\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-13 17:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) announced that its wholly owned unit, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., has initiated a Phase II clinical trial in mainland China for FXS7553, an orally administered small-molecule DPP-1 inhibitor targeting chronic obstructive pulmonary disease (COPD).</p>\n<p>FXS7553—formerly coded XH-S004—is being developed for multiple respiratory indications, including non-cystic fibrosis bronchiectasis, for which it is already in a separate Phase II study. To date, the group has invested approximately RMB 151.00 million in the compound’s research and development.</p>\n<p>No DPP-1 inhibitor has yet secured marketing approval in China, underscoring the molecule’s potential first-in-class positioning domestically. The programme remains subject to the standard clinical and regulatory review process, and the company highlights inherent uncertainties in drug development, including possible safety or efficacy hurdles that could disrupt progress.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1109029583","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109029583","pubTimestamp":1786614464,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) announced that its wholly owned unit, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., has initiated a Phase II clinical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药子公司启动新型DPP-1抑制剂FXS7553治疗COPD的II期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) announced that its wholly owned unit, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., has initiated a Phase II clinical trial in mainland China for FXS7553, an orally administered small-molecule DPP-1 inhibitor targeting chronic obstructive pulmonary disease (COPD).\nFXS7553—formerly coded XH-S004—is being developed for multiple respiratory indications, including non-cystic fibrosis bronchiectasis, for which it is already in a separate Phase II study. To date, the group has invested approximately RMB 151.00 million in the compound’s research and development.\nNo DPP-1 inhibitor has yet secured marketing approval in China, underscoring the molecule’s potential first-in-class positioning domestically. The programme remains subject to the standard clinical and regulatory review process, and the company highlights inherent uncertainties in drug development, including possible safety or efficacy hurdles that could disrupt progress.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109029583","isCrawlerRequest":true}